sermorelin+Ipamorelin
C$77.99
For Research Purposes Only
Sermorelin & Ipamorelin Peptide Blend
The Sermorelin & Ipamorelin blend synergistically enhances growth hormone (GH) secretion, supporting anabolic activity, metabolic regulation, and tissue repair.
Mechanism of Action
- Sermorelin (29 amino acids) functions as a synthetic analog of growth hormone-releasing hormone (GHRH), activating pituitary GHRH receptors to induce GH secretion and stimulate insulin-like growth factor-1 (IGF-1) production.
- Ipamorelin (5 amino acids) operates via the ghrelin pathway, targeting GHS-R1a receptors, enhancing GH release without affecting ACTH or prolactin synthesis.
- Distinct half-lives: Sermorelin (~12 min) triggers immediate GH release, while Ipamorelin (~2 hrs) extends GH secretion, ensuring sustained anabolic effects.
Research Insights
- Growth Hormone Modulation: Studies suggest Sermorelin increases GH levels by up to 107%, while Ipamorelin may enhance GH secretion 6000% over baseline.
- Lean Mass & Tissue Growth: Sermorelin has been linked to lean body mass gains (~1.26 kg), while Ipamorelin may stimulate appetite-driven weight increases (~17%).
- Bone Density: Ipamorelin has been correlated with increased bone mineral content, potentially supporting osteogenic activity.
Quantity
Chemical Properties
- Sermorelin: C₁₄₉H₂₄₆N₄₄O₄₂S MW: 3357.93 g/mol
- Ipamorelin: C₃₈H₄₉N₉O₅ MW: 771.86 g/mol
This optimized blend presents a dual-pathway approach to GH modulation, offering a compelling potential for metabolic enhancement, muscle regeneration, and tissue repair.
Refrence
National Center for Biotechnology Information. “PubChem Compound Summary for CID 16129620, Sermorelin” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Sermorelin
National Center for Biotechnology Information. “PubChem Compound Summary for CID 9831659, Ipamorelin” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin
Khorram, O., Laughlin, G. A., & Yen, S. S. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism, 82(5), 1472–1479. https://doi.org/10.1210/jcem.82.5.3943
Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
Lall, S., Tung, L. Y., Ohlsson, C., Jansson, J. O., & Dickson, S. L. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and biophysical research communications, 280(1), 132–138. https://doi.org/10.1006/bbrc.2000.4065
Sermorelin & Ipamorelin Peptide Blend is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.